Aurora kinase B inhibitors induce apoptosis secondary to polyploidization and have entered clinical trials as an emerging class of neocytotoxic chemotherapeutics. We demonstrate here that polyploidization neutralizes Mcl-1 function, rendering cancer cells exquisitely dependent on Bcl-XL/-2. This "addiction" can be exploited therapeutically by combining aurora kinase inhibitors and the orally bioavailable BH3 mimetic, ABT-263, which inhibits Bcl-XL, Bcl-2, and Bcl-w. The combination of ABT-263 with aurora B inhibitors produces a synergistic loss of viability in a range of cell lines of divergent tumor origin and exhibits more sustained tumor growth inhibition in vivo compared with aurora B inhibitor monotherapy. These data demonstrate that Bcl-XL/-2 is necessary to support viability during polyploidization in a variety of tumor models and represents a druggable molecular vulnerability with potential therapeutic utility.
Aurora kinase B inhibitors induce apoptosis secondary to polyploidization and have entered clinical trials as an emerging class of neocytotoxic chemotherapeutics. We demonstrate here that polyploidization neutralizes Mcl-1 function, rendering cancer cells exquisitely dependent on Bcl-XL/-2. This "addiction" can be exploited therapeutically by combining aurora kinase inhibitors and the orally bioavailable BH3 mimetic, ABT-263, which inhibits Bcl-XL, Bcl-2, and Bcl-w. The combination of ABT-263 with aurora B inhibitors produces a synergistic loss of viability in a range of cell lines of divergent tumor origin and exhibits more sustained tumor growth inhibition in vivo compared with aurora B inhibitor monotherapy. These data demonstrate that Bcl-XL/-2 is necessary to support viability during polyploidization in a variety of tumor models and represents a druggable molecular vulnerability with potential therapeutic utility.
apoptosis | aurora kinase | Bcl-XL | polyploidy A urora kinases B and C are part of the chromosomal passenger complex (CPC) that maintains the integrity of spindle assembly checkpoint (SAC) during cell cycle (1) . Pharmacologically disabling the SAC in tumor cells using small-molecule aurora B inhibitors induces apoptosis secondary to polyploidization (2) (3) (4) (5) , and aurora B inhibitors are being evaluated in clinical trials for the treatment of cancer. However, polyploidization is not an absolute commitment to apoptosis because polyploid cells spawn viable progeny, albeit far less frequently than diploid cells (6) . This raises concerns that the genetic reshuffling that occurs during polyploidization may drive the evolution of more aggressive secondary tumors. Thus, the elimination of polyploid cells may represent a means to improve the efficacy of aurora kinase inhibitors while minimizing the burden of genetically reshuffled tumor cells after therapy.
Here we have identified a druggable mechanism in cancer cells that is required to sustain polyploid cell viability. This mechanism hinges on the function of Bcl-XL/-2, which when disabled by siRNAs or small molecules, triggers the rapid demise of polyploid cancer cells. These data suggest that combining inducers of polyploidy, such as aurora kinase inhibitors, with agents that target Bcl-XL/-2 could be a viable strategy for cancer therapy and provides an example of a therapeutic drug combination that specifically exploits polyploidization.
Results VX-680/MK-0547 and ABT-263 Elicit Synergistic Cytotoxicity. Smallmolecule inhibitors that specifically target the aurora family of serine/threonine kinases are under clinical evaluation as monotherapy and will no doubt be combined with other chemotherapeutic agents. To experimentally identify agents that could be therapeutically combined with aurora kinase inhibitors, we screened VX-680, a pan-aurora inhibitor, in combination with 19 clinical and experimental cancer therapeutics for their effect on cell viability (Table S1 ). A unique synergistic activity was observed when VX-680 was combined with ABT-263, an orally bioavailable, small-molecule BH3 mimetic that inhibits Bcl-XL, Bcl-2, and Bcl-w ( Fig. 1 A and B and Fig. S1A ) (7, 8) . Bliss analysis showed that VX-680 was synergistic with ABT-263 in tumor cell lines irrespective of histological type and p53 status [e.g., A549 (lung carcinoma; TP53 WT ), EJ1 (bladder carcinoma; TP53 Mut ), D54MG (glioma; TP53 WT ), PC3 (prostate carcinoma; TP53 Mut ), HCT116 (colon carcinoma; TP53 WT ), and SW620 (colon carcinoma; TP53 Mut ); Fig. 1A and Fig. S1B ], indicating that the synergy observed for these two classes of oncology drugs may reflect a molecular susceptibility pervasive in cancer cells. Isobologram analysis of ABT-263/VX-680 combination in SW620 cells further confirmed the synergistic interaction of the two compounds over a wide dose range and compound ratios (Fig. 
S1 C and D).
Synergistic Activity of VX-680 and ABT-263 Can Be Fully Ascribed to the Combined Inhibition of Aurora B and Bcl-XL. VX-680 is a potent inhibitor of aurora A, B, and C kinases with K i(app) values of 0.6, 18, and 4.6 nM, respectively (3). It is, therefore, important to distill from the pan-aurora profile of VX-680 the aurora kinase activity that would suffice for synergy with ABT-263. Likewise, ABT-263 inhibits Bcl-XL, Bcl-2, and Bcl-w with similar potencies, displaying K i values of ≤0.5, ≤1, and ≤1 nM, respectively (7), and presents a similar complication. Therefore, we set out to deconvolute these activities and identify the activities that were sufficient for synergy using both siRNA and selective small molecules. Aurora B, but not aurora A, siRNA was synergistically antiproliferative in combination with ABT-263, although both siRNAs efficiently knocked down their respective targets ( Fig. 2A and Fig. S2 A and B) . Similar results were also obtained using additional siRNAs targeting aurora A and aurora B, indicating that the observed synergy is not a result of the off-target activity of siRNAs (Fig. S2 C and D) . MLN8054, a small-molecule inhibitor of aurora A, showed no synergy in combination with ABT-263 at aurora A-selective concentrations (<5 μM) (9, 10) . In contrast, synergy was observed when ABT-263 was combined with the aurora B-selective inhibitor, AZD1152 (Fig. 2 B and C) (4, 5) .
Although ABT-263 inhibits Bcl-2, Bcl-XL, and Bcl-w, it is relatively inactive vs. other antiapoptotic members of the Bcl-2 family, such as Mcl-1 and Bcl-A1. Because Bcl-2 and Bcl-XL are coexpressed in many human cancer cells, we used siRNA to determine which of the two ABT-263 targets, when inhibited, would phenocopy the synergistic activity observed for ABT-263 in combination with AZD1152. When transfected into HCT116 and EJ1 cells, Bcl-XL, but not luciferase, Bcl-2, or Mcl-1 siRNA exhibited a synergistic inhibition of cell growth in combination with AZD1152 or aurora B siRNA (Fig. 2 D-F and Fig. S2 E-G). Therefore, inhibition of Bcl-XL, but not Bcl-2, cooperates with aurora B inhibition to induce cell death in these tumor cell lines. Collectively, these data indicate that the synergistic activity of VX-680 and ABT-263 can be ascribed to inhibition of aurora B and Bcl-XL in solid tumor lines.
ABT-263 Triggers Rapid Apoptosis in Polyploid Cells. Either treatment with aurora B siRNA or AZD1152 induced pronounced polyploidization, and exposure of polyploid cells to ABT-263 resulted in rapid apoptosis (Fig. S3A and Movie S1). Because polyploidy represents the ultimate cell fate associated with sustained inhibition of aurora B, we set out to determine whether P PC3 NCI-H460  HCT116   EJ1  DLD1  D54MG  A549  PC3  NCI-H460  HCT116   EJ1  DLD1  D54MG  A549   ABT-263  ABT-751  ABT-888  ABT-100  Ritonavir  A-443654  A-407876  BI 2536  Rapamycin  Etoposide   ABT-263  ABT-751  ABT-888  ABT-100  Ritonavir  A- Bcl-XL inhibition and polyploidization were synergistically cytotoxic, independently of aurora B. The CPC is an epistasis group comprising aurora B, survivin, inner centromere protein (INCENP), and borealin and represents the functional core of the SAC. Disruption of the CPC results in cytokinesis failure and polyploidy. Knockdown of INCENP induced polyploidy (Fig. S3 A and B) and was synergistically antiproliferative with Bcl-XL knockdown (Fig. 3A) , suggesting that inhibition of Bcl-XL is deleterious for polyploid cells. However, targeting INCENP with siRNA also delocalizes aurora B and inhibits its activity. Therefore, the effect of INCENP siRNA cannot be completely dissociated from disruption of aurora B. To determine whether polyploidy per se was sufficient to sensitize cells to Bcl-XL inhibition, we treated cells with AZD1152 to induce polyploidy, washed out the drug, and then cultured the polyploid cells until aurora B activity was restored. Polyploidy was evidenced by the gross morphological increase in cell size and multinucleation (Fig. 3B ) and the elevated expression of p53 (Fig. 3C) , a surrogate marker of polyploidization in cell harboring wild-type p53. After AZD1152 washout, histone H3 phosphorylation returned to untreated levels, indicating that aurora B activity had been fully restored in polyploid cells (Fig. 3C ). ABT-263 induced caspase-3 activity and loss of viability in polyploid, but not naive cells, independently of the activation status of aurora B (Fig. 3 D and E). Polyploid cells were the specific targets of ABT-263 because the polyploid, but not diploid, population of cells was eliminated when measured by flow cytometry (Fig. S3C ). Furthermore, ABT-263 triggered robust apoptosis in cells made polyploid by treatment with the myosin II inhibitor blebbistatin and the actin polymerization inhibitor dihydrocytochalasin B (DHCB; Fig. S4 A-C). Because blebbistatin and DHCB induce polyploidization independent of aurora B inhibition, these data collectively suggest that the polyploid phenotype renders cell survival dependent on the antiapoptotic activity of Bcl-XL.
Polyploidization Shifts the Survival Burden to Bcl-XL. The multidomain apoptotic proteins Bax and Bak together constitute an obligatory portal to apoptosis (11, 12) . To begin to shed light on the mechanisms through which Bcl-XL neutralization elicits cell death in polyploid cells, we examined the activation of Bax and Bak in cells rendered polyploid with AZD1152 using antibodies that selectively recognize the active Bax and Bak conformers. Addition of ABT-263 to polyploid HCT116 cells rapidly and synergistically induced Bax and Bak activation (Fig. 4A ). The activation of Bax and Bak was followed by mitochondrial release of cytochrome C into the cytosol, a decisive event in the commitment to apoptosis (Fig. 4B) . The proapoptotic function of Bax and Bak is normally inhibited by antiapoptotic members of the Bcl-2 family, such as Bcl-XL, Bcl-2, and Mcl-1, and it is the balance of interactions between BH3-only and multidomain proteins that sets the threshold for apoptosis through the intrinsic pathway (13, 14) . In contrast to what was observed in polyploid cells, neutralization of Bcl-XL is not normally sufficient to trigger apoptosis in diploid or aneuploid cells derived from most solid tumors (20) . To elucidate how polyploidization engages elements of the apoptotic machinery, we monitored the Bcl-2 network at the mRNA and protein level in response to polyploidization. Hierarchical clustering of Bcl-2 network genes indicated that the transcriptional profiles of polyploidization (VX-680 and AZD1152) were consistently most similar compared with aurora A inhibition (MLN8054), although they differed across cell lines (Fig. S5A) . At the protein level, a number of proapoptotic BH3-only proteins were up-regulated after polyploidization (Fig. 4C ). An increase in Puma and Noxa was a conserved response across cell lines, whereas tBid, Bik, Bim, and Bax increased in a cell line-dependent manner. Although only subtle changes in expression were observed for Bcl-2 and Bcl-XL, Mcl-1 was significantly reduced in HCT116 and SW620, but not D54MG cells (Fig. 4C ). The down-regulation of Mcl-1 during polyploidization does not seem to result from accelerated protein degradation ( Fig. S5 B and C) , and the precise mechanism of polyploidy-dependent Mcl-1 regulation is not clear. Noxa binds to and is a specific antagonist of the antiapoptotic function of Mcl-1 (15) . The up-regulation of Noxa was a common response to polyploidization in all cell lines tested. This is predicted to neutralize Mcl-1, even in D54MG cells where the abundance of Mcl-1 was not reduced (Fig. 4C ). Up-regulation of Noxa was also observed in HCT116 cells rendered polyploid by treatment with blebbistatin and DHCB (Fig. S4B) . Collectively, polyploidization induced effectors of apoptosis while compromising Mcl-1 function, directly through down-regulation of Mcl-1 and/or indirectly by up-regulating Noxa. Because cell viability is maintained during this period of polyploidization, we infer that the burden to support viability is shifted from Mcl-1 to Bcl-XL/-2. Although gene expression represents one level at which the Bcl-2 network is regulated, the collection of binding events between pro-and antiapoptotic proteins ultimately determines the balance between survival and apoptosis. We therefore empiri-
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A AZD1152 DMSO cally defined the Bcl-XL and Mcl-1 interactomes and monitored the effect of polyploidization on these interactions. HCT116 cells were treated with DMSO, ABT-263, AZD1152, or AZD1152 and ABT-263. Endogenous Bcl-XL or Mcl-1 was then immunoprecipitated, and the immune complexes were analyzed by ingel tryptic digestion and liquid chromatography-tandem mass spectrometry. We compiled the protein identifications from all treatments, yielding a composite interactome that represents all Bcl-XL and Mcl-1 interactions detected (Fig. S5D ). Interactions were subsequently confirmed by coimmunoprecipitation and immunoblotting under each treatment condition (Fig. 4 D and E) . None of the coimmunoprecipitated proteins were detected in anti-S6K1 immunoprecipitates using an IgG isotype-matched antibody (Fig. 4 D and E), underscoring the specificity of these interactions. In polyploid cells (AZD1152-treated), the interactions of Bik and tBid with Bcl-XL were increased, whereas the binding of Bad, Bim, Bax, and Puma was unchanged (Fig. 4D ), indicating that Bcl-XL was increasingly burdened by proapoptotic proteins upon polyploidization. Consistent with the reduction of Mcl-1 protein level, a reduced amount of Mcl-1 was captured by immunoprecipitation in polyploid cells (Fig. 4E) . In parallel, a stoichiometric increase in Noxa binding during polyploidization was also observed (Fig. 4E) . Furthermore, the association of Mcl-1 with Bim and Puma was significantly attenuated in polyploid cells (Fig. 4E) , suggesting that the reduction of Mcl-1 and concomitant increase of Noxa was sufficient to partially neutralize Mcl-1. In addition, maintaining high levels of Mcl-1 during polyploidization desensitized polyploid cells to ABT-263 treatment, thus providing further support for a causative role of Mcl-1 neutralization in sensitivity to ABT-263 (Fig. S6) .
Identification of Bcl-2 Network Components Required for Bcl-XL/
Aurora B Inhibitor Synergy. Although multiple Bcl-2 family proteins were modulated by polyploidization at the levels of expression and/or protein-protein interaction, it was unclear which were essential to induce death of polyploid cells upon Bcl-XL inhibition. We therefore carried out an siRNA screen, emphasizing the Bcl-XL and Mcl-1 interactomes, to identify elements of the Bcl-2 network that, upon knockdown, could rescue viability in the presence of dual inhibition of aurora B and Bcl-XL in the solid tumor line HCT116. Multiple siRNAs targeting Noxa, Bax, and to a lesser extent those targeting Bak, were found to rescue polyploid cells from ABT-263-mediated cell death (Fig. 5 A and B) . In fact, siRNA-mediated depletion of Noxa and Bax in several cell lines rendered polyploid cells resistant to Bcl-XL/-2 inhibition (Fig. S7 A and B) . These data imply causal roles for Noxa and Bax in polyploid cell death after Bcl-XL inhibition.
To further understand the role of Noxa as an effector of polyploid cell apoptosis, we compared the Mcl-1 interactomes before and after polyploidization in cells transfected with a control or Noxa-targeting siRNA. As before, a reduction of Mcl-1 protein and a stoichiometric increase in Noxa binding to Mcl-1 was observed in cells made polyploid using AZD1152 ( Aurora kinase inhibitors have proven to be efficacious in preclinical models, so it was unclear whether targeting Bcl-XL in polyploid tumor cells in vivo would yield efficacy superior to aurora kinase inhibitor monotherapy. We assessed this by comparing the antitumor activity of AZD1152 with AZD1152 in combination with ABT-263 under a stringent in vivo setting: at the maximum tolerated dose of AZD1152 in large, well-established tumors (≈500 mm 2 ). AZD1152 as a single agent produced significant tumor growth inhibition in the HCT116 colon carcinoma model, although tumors started to recover from therapy within 1 wk. In contrast, the combination regimen of AZD1152 plus ABT-263 produced a rapid and sustained tumor regression that persisted for at least 2 wk (Fig. 6A) . In tumors that were pretreated for 3 d with AZD1152, we observed an induction of p53, a surrogate marker of polyploidization (Fig. S8A) . The active Bax conformer was detected in tumors within 4 h of administration of ABT-263 when administered in combination with AZD1152, but not in animals administered ABT-263 alone and only slightly in animals that received AZD1152 alone. These data indicate that aurora B and Bcl-XL inhibition cooperatively induces apoptosis in vivo (Fig. S8A) .
Whereas most solid tumors rely heavily on Bcl-XL rather than Bcl-2 to inhibit apoptosis, the DoHH2 diffuse large B cell lymphoma overexpresses Bcl-2 as a result of a t(14;18) translocation, and survival seems to be relatively Bcl-2 dependent (16, 17) . AZD1152 and ABT-263 exhibited synergistic cytotoxicity in DoHH2 cells in vitro (Fig. S8 B and C) , and polyploidization led to a reduction in Mcl-1 and up-regulation of Noxa (Fig. S8D) . In large DoHH2 tumors (600 mm 2 ), AZD1152 induced a tumor regression that persisted for 10 d. However, when administered in combination with ABT-263, AZD1152 caused a more complete tumor regression that persisted through the duration of the study (Fig. 6B) . Thus, even in tumors that overexpress Bcl-2, ABT-263 may improve efficacy of aurora kinase inhibitors. Robust in vivo synergy in the DoHH2 model was also observed using an unrelated aurora B inhibitor, VX680, in combination with ABT-263, suggesting that the observed synergy is not compound-dependent (Fig. S8E) .
Discussion
Although most solid tumor cells are not sensitive to the neutralization of Bcl-XL, polyploidization engenders an "addiction" to Bcl-XL. This occurs through modulation of gene expression and protein-protein interactions, which increasingly burden Bcl-XL while neutralizing Mcl-1 (Fig. S9A) . The dependence upon Bcl-XL leaves polyploid cell viability particularly vulnerable to ABT-263, which targets this survival mechanism and requires Bax to elicit apoptosis (Fig. 5 A and B) . This conclusion is supported by the observation of Minn et al. (18) that ectopic expression of Bcl-XL provides a survival advantage to polyploid murine FL5.12 cells after mitotic spindle damage.
It has been shown that Bcl-XL and Mcl-1 play complementary roles to maintain the cellular balance of life and death. In fact, the simultaneous inhibition of Mcl-1 and Bcl-XL/-2 is lethal in cells of solid and hematologic tumor origin (19) (20) (21) . Although it is sufficient to cause Bcl-XL dependence, the inhibition of Mcl-1 during polyploidization seems incomplete, because apoptosis induced by AZD1152/ABT-263 is augmented by Mcl-1 knockdown (Fig. 5 D and E) . In view of this, we speculate that in tumors in which the antiapoptotic capacity of Mcl-1 is already limited (e.g., tumors expressing low levels of Mcl-1 or high levels of Bim), a polyploidy inducer such as AZD1152 will likely cause a more complete neutralization of Mcl-1 function, thus yielding a more effective combination therapy.
Although the exquisite Bcl-XL dependency of polyploid cells can be explained by Mcl-1 neutralization and the heightened burden placed on Bcl-XL, precisely how apoptosis is triggered by Bcl-XL inhibition is unclear. A comparison of Bcl-XL interactomes in polyploid cells before and after exposure to ABT-263 indicates that multiple proapoptotic BH3-only proteins, including Bik, Bad, Bim, and Puma, are displaced from Bcl-XL (Fig. 4D) . However, siRNAmediated knockdown of these proteins individually does not protect polyploid cells from ABT-263-induced cell death (Fig. 5 A  and B) . We presume that it is either the composite action of several BH3-only proteins displaced by ABT-263 or some as-yet unidentified effectors that triggers mitochondrial apoptosis in polyploid cells. Intriguingly, an increase in Bax and tBid binding to Bcl-XL is evident in polyploid cells exposed to ABT-263 (Fig. 4D) . Whether the increased binding of Bcl-XL to Bax and tBid occurs subsequent to the onset of apoptosis or is causal in the initiation of polyploid cell death will require further study.
Although several aurora B inhibitors have advanced into clinical trials, what has not yet garnered much attention is the liability of inducing polyploidy in an already rapidly evolving tumor. Polyploidization, by altering genomic stoichiometry, accelerates evolutionary processes and fuels adaptation to severe phenotypes in eukaryotes, most notably cytokinesis deficiency (6) . This raises concerns that, in tumor cells, induction of polyploidy may itself facilitate adaptation to and escape from aurora B inhibitors, which act by bypassing cytokinesis. The vulnerability of tumor cells to Bcl-XL inhibition during polyploidization may represent a means to stem the evolution of genetically reshuffled tumor cells that might be better equipped to resist therapy. It is noteworthy that AZD1152 treatment only had a marginal impact on Mcl-1 and Noxa and consequently did not produce synergistic cytotoxicity in combination with ABT-263 in the nontransformed cell line IMR-90 ( Fig. S9 B and C) . This result suggests that the combination of polyploidy inducers and ABT-263 may display enhanced cytotoxicity in tumor vs. normal tissues.
In summary, we demonstrate here that the prosurvival function of Mcl-1 in cancer cells is neutralized secondary to polyploidization, which places cell survival strictly dependent on the remaining antiapoptotic proteins, namely Bcl-XL and/or Bcl-2. This represents a bona fide therapeutic vulnerability because combining aurora B and Bcl-XL/-2 inhibitors produces synergistic antiproliferative activity in vitro and enhanced efficacy in vivo. Moreover, these data provide an example of a therapeutic application that specifically exploits and targets the polyploid phenotype for the treatment of cancer.
Experimental Procedures
Determination of Drug-Drug Interactions. Synergistic activities of VX-680 and chemotherapeutic agents were determined using the Bliss additivity model, whereby the combined response C of both agents with individual effects A and B is C = A + B -(A × B), where A and B represent the fractional inhibition between 0 and 1. Combined response scores greater than 15 were considered synergistic; 0-15 were considered no interaction, and less than −15 were considered antagonistic.
Reagents. All antibodies were purchased from commercial sources. siRNAs were purchased from Dharmacon. All small-molecule inhibitors were purchased from AG Scientific or synthesized at Abbott Laboratories.
siRNA Transfections. Cells were seeded at 5,000 per well in 96-well plates in antibiotic-free growth medium and cultured overnight. The following day, cells were transfected with siRNA oligos using Lipofectamine RNAiMAX transfection reagent (Invitrogen) or DharmaFECT transfection reagent according to the manufacturer's recommendations.
Cell Viability Assay and Caspase 3/7 Assay. Cell viability was determined using the CellTiter-GLO luminescence assay (Promega) according to the manufacturer's suggested protocol. Caspase-3 activity was determined using the Caspase-GLO 3/7 Assay (Promega) in tandem with the CellTiter-GLO viability assay (Promega).
Please refer to SI Experimental Procedures for additional information. (Table S1 ). Synergistic activities of VX-680 and chemotherapeutic agents were determined using the Bliss additivity model (1), whereby the combined response C of both agents with individual effects A and B is C = A + B − (A × B) , where A and B represent the fractional inhibition between 0 and 1. Combined response scores greater than 15 were considered synergistic; 0-15 were considered no interaction, and less than −15 were considered antagonistic.
Antibodies. All antibodies were purchased from commercial sources as follows: antibodies against inner centromere protein (INCENP) (clone A841; catalog no. 2786), histone H3 (catalog no. 9712), histone H3-(pSer 10 ; catalog no. 9701), Bik (catalog no. 4592), Puma (catalog no. 4976), and Bak (catalog no. 3814) were from Cell Signaling Technology; antibodies against aurora B (catalog no. 1788-1) and Bad (catalog no. 1541-1) were from Epitomics; antibodies against aurora A (catalog no. 610938), p53 (catalog no. 554294), cytochrome C (catalog no. 556433), Bid (catalog no. 550365), Bim (catalog no. 559685), and Ral-A (catalog no. 610221) were from BD Biosciences; antibodies against Bcl-2 (catalog no. sc-7382), Bcl-XL (catalog no. sc-7195), Mcl-1 (catalog no. sc-819), and S6K1 (catalog no. sc-230) were from Santa Cruz Biotechnology; antibodies against Bax (catalog no. ab7977-1) were from Abcam; antibodies against Noxa (catalog no. IMG-349A) were from Imgenex; antibodies against the active Bax conformer (6A7; catalog no. B8429) were from Sigma; antibodies against the active Bak conformer (Ab2; catalog no. AM04) were from Calbiochem; antibodies against β-actin (catalog no. AF4000) were from R&D Systems.
Small Molecules and siRNAs. Active components of the clinical drugs carmustine (BCNU), doxorubicin, gemcitabine, etoposide, 5-fluorouracil, alimta, rapamycin, and the previously disclosed Abbott compounds, ABT-751 (tubulin inhibitor), ABT-888 (poly-ADP ribose polymerase inhibitor) (2), ABT-263 (Bcl-2 family inhibitor) (3), ritonavir (4), A-443654 (AKT inhibitor) (5), and A-407846 (histone deacetylase) (6) were obtained from Abbott's Compound Depository. 17-AAG was purchased from AG Scientific. The chemical structures of MLN8054 (7), AZD1152 (8) , and VX-680/ MK-0457 (9) and BI 2536 have been disclosed. These compounds were synthesized at Abbott Laboratories for comparative purposes. AZD1152-hydroxyquinazoline pyrazol anilide (HQPA) is rapidly converted from the dihydrogen phosphate prodrug AZD1152 in the presence of plasma (8) . For all studies, AZD1152-HQPA was used and referred to as AZD1152.
siRNAs against Bcl-2, Bcl-XL, Mcl-1, aurora A, aurora B, INCENP, Bik, Noxa, Bax, Bak, Puma, Bad, and Bim were purchased from Dharmacon. For each target, a set of four ON-TARGET Plus siRNAs were prescreened for target knockdown and off-target cytotoxicity. siRNAs that triggered more than a 70% reduction of target protein without causing more than a 10% offtarget growth inhibition in a 72-h proliferation assay were selected for all siRNA-related studies. The most potent siRNA against each target was used in experiments in which only one siRNA/target was used. The control, nontargeting siRNA and a previously described luciferase siRNA (10) were also purchased from Dharmacon. C.B.-17 scid-bg (scid-bg) or C.B.-17 scid (scid) mice were obtained from Charles River Laboratories at 5 to 6 wk of age and used for studies when greater than 8 wk of age and/or ≈20 g in size. All animal studies were conducted in a specific pathogen-free environment in accordance with the Internal Institutional Animal Care and Use Committee (accredited by the American Association of Laboratory Animal Care under conditions that meet or exceed the standards set by the US Department of Agriculture Animal Welfare Act, Public Health Service policy on humane care and use of animals, and the National Institutes of Health guide on laboratory animal welfare. Overt signs of dehydration, lack of grooming, lethargy, >15% weight loss, and tumor volume >20% of body weight were used to determine tumor endpoint.
The tumor cell lines HCT116 and DoHH2 were routinely tested for Mycoplasma and confirmed to be microbe free by infectious microbe PCR amplification test (Missouri Research Animal Diagnostic Laboratory) before in vivo inoculation. Cells were grown in RPMI supplemented with 1 mM L-glutamine and 10% FBS, maintained at 37°C in a humidified atmosphere equilibrated with 5% CO 2 , 95% air, and used between passages 3 and 7 when in log phase for tumor cell inoculation. Cells (1 × siRNA Transfections. Typically, cells were seeded at 5,000 per well in 96-well plates in antibiotic-free growth medium and cultured overnight. The following day, cells were transfected with siRNA oligos using Lipofectamine RNAiMAX transfection reagent (Invitrogen) or DharmaFECT transfection reagent according to the manufacturer's recommendations. Individual siRNAs were transfected at a final concentration of 10 nM. For immunoblotting experiments, cells were cultured for a further 3 d, then lysates were prepared. For siRNA/drug combinations, cells were treated with compound 24 h after transfection, then cultured for a further 72 h. For long-term polyploidization, cells were cultured for up to 10 d after transfection.
Cell Viability Assay and Caspase 3/7 Assay. Cell viability was determined using the CellTiter-GLO luminescence assay (Promega) according to manufacturer's suggested protocol. Generally, cells were seeded at >90% viability (as determined by trypan blue exclusion) into 96-well plates overnight, treated with compounds or siRNAs for indicated duration, and the overall cell viability was determined by measuring luminescence.
Caspase-3 activity was determined using the Caspase-GLO 3/7 Assay (Promega) in tandem with the CellTiter-GLO viability assay (Promega). Parallel experiments were performed, whereby in one experiment caspase-3/7 activity was measured, and in the other, cell viability was determined. Because caspase-3/7 activity on a per-cell basis reflects both the specific activity of the caspase-3 enzyme and the number of viable cells, the data are expressed as caspase-3/7 activity divided by cell viability.
Immunofluorescence. Cells were seeded in collagen-coated 96-well plates, treated as indicated, washed three times in PBS, then fixed in 3.7% formaldehyde for 10 min at room temperature. Cells were rinsed three times in PBS, then permeablized in PBS containing 0.5% Triton X-100 for 5 min. DNA was stained using a 1:10,000 dilution of Hoechst 33342 (Molecular Probes, catalog no. H-3570) in the dark for 30 min. Cells were washed three times with PBS, then imaged by fluorescence microscopy.
Flow Cytometry. After treatment, cells were trypsinized and washed once with PBS. Cells were resuspended in DNA staining solution (50 μg/mL propidium iodide, 0.1 mg/mL RNase, 0.1% BSA, and 0.1% Triton X-100 in PBS), incubated in the dark for 20 min, then analyzed by flow cytometry using a BD LSRII flow cytometer (BD Biosciences).
Retroviral Transduction. HCT116 cells expressing FLAG-Mcl1 were generated by infecting parental HCT116 cells with VSV-Gpseudotyped retrovirus. Briefly, plasmids encoding pLHCX-FLAG-Mcl1 and VSV-G were cotransfected into the Bosc23 packaging cell line using the FugeneHD (Roche) transfection reagent. Forty-eight-hour retroviral supernatants were collected and added to parental HCT116 cells at a multiplicity of infection (MOI) of 0.25 or 1. Hygromycin-resistant HCT116 cells were selected and stable transgene expression confirmed by anti-Mcl1 and anti-FLAG immunoblot.
Immunoblotting and Immunoprecipitation. Cell lysates were either prepared using a CHAPS lysis buffer [10 mM Hepes (pH 7.4), 150 mM NaCl, 1% CHAPS] or a cell extraction buffer containing 1% Triton X-100, 0.1% SDS, and 0.5% deoxycholate (Invitrogen). All buffers were supplemented with protease and phosphatase inhibitor mixtures (Sigma) before use. For immunoblotting, lysates were mixed with 3× loading buffer (Cell Signaling Technology), and equal amounts of protein were separated by electrophoresis on Bis/Tris gels (Invitrogen). For immunoprecipitation, lysates were prepared in CHAPS lysis buffer, and >4 mg of cell lysate was mixed with at least 8 μg of immunoprecipitating antibody overnight at 4°C. The following day, 30 μL of a Protein A-or Protein G-agarose slurry was added for an additional 2 h. Immunoprecipitates were washed three times in CHAPS lysis buffer and heated in 1.5× loading buffer at 95°C for 5 min.
Purification of Cytosol. Approximately 20 × 10 6 cells were rinsed once in ice-cold PBS, trypsinized, and centrifuged for 2 min at 1,300 × g at 25°C. Cell pellets were rinsed once with PBS and transferred to microcentrifuge tubes. The pellet was allowed to swell in 200 μL homogenization buffer [10 mM Hepes (pH 7.4), 250 mM D-mannitol, 1 mM EGTA, 10 mM KCl, and 5 mM MgCl 2 with phosphatase and protease inhibitors] for 30 min, then dounce homogenized with 50 strokes using a type-B pestle. Cell homogenates were centrifuged twice at 1,000 × g for 5 min at 4°C to pellet nuclei and cell debris. The supernatant was centrifuged at 10,000 × g for 10 min at 4°C. The pellet from this spin was designated "mitochondria" and further extracted in 80 μL of CHAPS lysis buffer. Extraction of mitochondria was performed on ice by repeatedly vortexing the samples for 1 min each for ≈20 min. The final extract was clarified by centrifugation at 14,000 × g for 10 min at 4°C to remove any contaminating cell debris. The 10,000 × g supernatant containing cytosol and low-density membranes was centrifuged again at 100,000 × g (55,000 rpm in a TLA 120.2 rotor) for 1 h to pellet membranes. The supernatant was designated "cytosol" and boiled directly in sample buffer.
Gene Expression Analysis by Microarray. Frozen cell pellets were lysed, and total RNA was isolated using the QIAshredder and RNeasy columns (Qiagen). Labeled cRNA was prepared according to the microarray manufacturer's protocol and hybridized to human genome U133A 2.0 arrays (Affymetrix). The microarray data files were loaded into Rosetta Resolver software for analysis, and the intensity values for all probesets were normalized using the Resolver's Experimental Definition. Clustering analysis within Resolver used the Agglomerative algorithm and Pearson correlation for the similarity measure, using genes that had a 1.5-fold change or higher in one treatment condition. Only differences with a P value of <0.001 are shown. For the pathway analysis, a 1.5-fold cutoff was applied, and a 5% false discovery rate was used for P value cutoff.
Mass Spectrometric Analysis of Immunoprecipitated Proteins. Endogenous Bcl-XL and Mcl-1 were immunoprecipitated from HCT116 cells. Samples to be processed for mass spectrometry were loaded into every other well of a 10-well × 1 mm 4-12% Bis/Tris gel (Invitrogen) to reduce lateral contamination. The gels were run at a constant 200 V in Mops running buffer for 45-60 min, then fixed in a solution of 50% methanol and 7% acetic acid for 15 min. After rinsing in water, the gels were treated with Sypro Ruby protein gel stain (Invitrogen) for 3 h at room temperature. Once completed, the gels were destained in a solution of 10% methanol and 7% acetic acid for 10 min, followed by washing and incubation in water for 30 min. Protein bands were subsequently imaged on a Fuji imager using the green channel.
Each lane on the gel was manually cut into 24 equally sized pieces, placed into a 96-well plate, and minced. The minced gel pieces were subjected to in-gel tryptic digestion at 37°C for 5 h using a Perkin-Elmer MassPrep unit and sequencing grade modified trypsin (6 ng/μL). The extracted peptides for each sample were lyophilized before resuspension in 10 μL of a solution of 5% acetonitrile and 0.1% formic acid. Resuspended samples (9.5 μL) were injected onto a 15-cm analytical capillary column (i.d. 75 μm, 5-μ particle size, 200 Å pore size) packed with Michrom C18AQ magic reversed-phase resin. The peptides were eluted using an Eiksigent nano-LC unit in a 35-min linear gradient (15-35% acetonitrile in 0.1% formic acid). Hydrophobic peptides were subsequently removed by increasing the acetonitrile composition from 35% to 80% over the next 5 min. The eluent was directed into the orifice of a linear trap quadrupole mass spectrometer (ThermoFisher). Scans were collected in datadependent double-play mode for the duration of the chromatographic separation.
Each liquid chromatography-tandem mass spectrometry (LC-MS/MS) data file was searched using Mascot Daemon v.2.2 against the National Center for Biotechnology Information nonredundant database restricted to the mammalian taxonomy. Peptides of 2 + to 3 + charge state were searched, with a maximum of two missed trypsin cleavages, carboxyamidomethyl as a fixed modification, oxidized methionine as a variable modification, and a mass window of +1.2 Da for intact peptides and +0.8 Da for ions generated from MS/MS. The Mascot search results for each data file were compiled by gel lane in Scaffold v.1.0 using the MudPIT compilation feature to yield protein identifications by treatment.
An interactome map of the Bcl-2 network was constructed manually using Ingenuity Pathway Analysis software (Ingenuity Systems). The composite of all protein identifications returned from Bcl-XL immunoprecipitates under all treatment conditions was applied to the Bcl-2 network map. Mcl-1 immunoprecipitates were analyzed similarly. Movie S1. HCT116 cells were incubated in medium containing 1uM AZD1152 for 72 h to induce polyploidy. Cells were then cultured in the presence of 1 μM ABT-263 and imaged by time-lapse video microscopy. Time stamp indicates hours and minutes after the addition of ABT-263.
Movie S1 Table S1 . VX-680 (1 μM) was screened in combination with dose-response curves of 19 clinical or experimental cancer therapeutics for their impact on cell viability 
